Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Sanofi’s Soliqua Edges Out Competitors in Blood Sugar Control Trial

Sanofi presented data from the company’s Phase III LixiLan-G trial demonstrating that Soliqua/Suliqua showed superior decrease of average blood sugar level (HbA1c) after 26 weeks compared to other GLP-1 receptor agonists.

Read More »

Abbott device helps in cutting blood sugar in type 2 diabetics: study

Insulin-dependent patients with T2D saw a significant drop in blood sugar levels after wearing Abbott’s continuous glucose monitoring system compared with those who use routine fingerstick testing.

Read More »

Zealand Pharma’s Severe Hypoglycemia Treatment Hits the Mark in Another Phase III Trial

Shares of Zealand Pharma A/S were up more than 2 percent after the company announced that dasiglucagon, a potential treatment for severe hypoglycemia, hit the mark in a Phase III study.

Read More »

Novo Nordisk Q1 2019 profit tops forecast

Danish drugmaker Novo Nordisk beat first-quarter 2019 operating profit forecasts, helped by higher sales of the company’s biggest new drug hope, a treatment for type 2 diabetes.

Read More »

Morning exercise, short breaks from sitting lower high blood pressure

Combining 30 minutes of morning exercise with short walking breaks throughout the day may help control blood pressure.

Read More »

Why Type One Diabetes Patients Need Closed Loop Insulin Systems

For a while now there has been a heated debate surrounding hybrid and closed loop insulin systems.

Read More »

Many diabetics needlessly test blood sugar at home

One in seven people with type 2 diabetes may be needlessly testing their blood sugar at home several times a day, a U.S. study suggests.

Read More »

AstraZeneca’s Farxiga curbs heart failure, kidney risks

The largest clinical trial so far to assess a new class of diabetes pills shows that AstraZeneca’s Farxiga can prevent heart failure and cut the risk of kidney problems in a broad range of patients.

Read More »

Lilly’s two-in-one diabetes product data impresses

Eli Lilly’s new two-in-one diabetes drug was successful in lowering blood sugar and reducing weight, sending the company’s shares to a record high and weighing on those of arch-rival Novo Nordisk.

Read More »

Adults need a regular bedtime, too

Adults who have a regular bedtime are likely to weigh less than those who do not, to have lower blood sugar and to face a lower risk of heart disease and diabetes, according to a U.S. study.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom